Cargando…

Fosfomycin and Comparator Activity Against Select Enterobacteriaceae, Pseudomonas, and Enterococcus Urinary Tract Infection Isolates from the United States in 2012

INTRODUCTION: Fosfomycin is a broad-spectrum cell wall active agent that inhibits the MurA enzyme involved in peptidoglycan synthesis and is FDA-approved for treatment of uncomplicated urinary tract infections (UTIs) caused by Escherichia coli and Enterococcus faecalis in women. Data regarding the s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Keepers, Tiffany R., Gomez, Marcela, Celeri, Chris, Krause, Kevin M., Biek, Donald, Critchley, Ian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5446363/ https://www.ncbi.nlm.nih.gov/pubmed/28285420 http://dx.doi.org/10.1007/s40121-017-0150-5

Ejemplares similares

Effect of In Vitro Testing Parameters on Ceftazidime-Avibactam Minimum Inhibitory Concentrations
por: Keepers, Tiffany R., et al.
Publicado: (2015)

1525. Evaluation of Clinical Outcomes With Fosfomycin for E. coli and Non-E. coli Enterobacteriaceae Urinary Tract Infections
por: Lee, Tiffany, et al.
Publicado: (2018)

Plazomicin Is Active Against Metallo-β-Lactamase-Producing Enterobacteriaceae
por: Serio, Alisa W, et al.
Publicado: (2019)

2062. Evaluation of Susceptibility Testing Methods for Fosfomycin Against Enterobacteriaceae and Pseudomonas aeruginosa
por: De La Cadena, Elsa Piedad, et al.
Publicado: (2018)

Experience with fosfomycin in the treatment of complicated urinary tract infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae
por: Bielen, Luka, et al.
Publicado: (2019)

2261. Oral Fosfomycin for Treatment of Urinary Tract Infections Due to Extended-Spectrum β-Lactamase and Carbapenem-Resistant Enterobacteriaceae
por: Hefler, Jade L, et al.
Publicado: (2019)

Susceptibility profile, resistance mechanisms & efficacy ratios of fosfomycin, nitrofurantoin & colistin for carbapenem-resistant Enterobacteriaceae causing urinary tract infections
por: Amladi, Anushree Ulhas, et al.
Publicado: (2019)

Oral and intravenous fosfomycin in complicated urinary tract infections
por: López-Montesinos, Inmaculada, et al.
Publicado: (2019)

Mobile fosfomycin resistance genes in Enterobacteriaceae—An increasing threat
por: Zurfluh, Katrin, et al.
Publicado: (2020)

Fosfomycin for management of persistent female lower urinary tract infection
por: Joob, Beuy, et al.
Publicado: (2018)

Oral and Intravenous Fosfomycin for the Treatment of Complicated Urinary Tract Infections
por: Zhanel, George G., et al.
Publicado: (2020)

Assessing the Emergence of Resistance in vitro and Invivo: Linezolid Combined with Fosfomycin Against Fosfomycin-Sensitive and Resistant Enterococcus
por: Li, Yaowen, et al.
Publicado: (2022)

High-Level Fosfomycin Resistance in Vancomycin-Resistant Enterococcus faecium
por: Guo, Yan, et al.
Publicado: (2017)

Oral fosfomycin for treatment of urinary tract infection: a retrospective cohort study
por: Matthews, Philippa C., et al.
Publicado: (2016)

Cost-Effectiveness Analysis of Fosfomycin for Treatment of Uncomplicated Urinary Tract Infections in Ontario
por: Perrault, Louise, et al.
Publicado: (2017)

124. Microbiological Outcomes With Plazomicin (PLZ) Versus Meropenem (MEM) in Patients With Complicated Urinary Tract Infections (cUTI), Including Acute Pyelonephritis (AP) in the EPIC Study
por: Keepers, Tiffany R, et al.
Publicado: (2018)

A Comparative Study of Urinary Tests and Cultures for the Effectiveness of Fosfomycin in Catheter-Related Urinary Tract Infections
por: Jo, Jung Ki, et al.
Publicado: (2022)

Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial
por: Gágyor, Ildikó, et al.
Publicado: (2015)

Multiple-Dose Oral Fosfomycin for Treatment of Complicated Urinary Tract Infections in the Outpatient Setting
por: Derington, Catherine G, et al.
Publicado: (2020)

Pharmacokinetics of fosfomycin in patients with prophylactic treatment for recurrent Escherichia coli urinary tract infection
por: Kuiper, Sander G, et al.
Publicado: (2020)

1526. Oral Fosfomycin Use for Urinary Tract Infections and Its Clinical Impact on Hospital Stay
por: Mai, Christina, et al.
Publicado: (2018)

Efficacy and Safety of Oral Fosfomycin-Trometamol in Male Urinary Tract Infections with Multidrug-Resistant Enterobacterales
por: Bouiller, Kévin, et al.
Publicado: (2022)

Real-Life Comparison of Fosfomycin to Nitrofurantoin for the Treatment of Uncomplicated Lower Urinary Tract Infection in Women
por: Shafrir, Asher, et al.
Publicado: (2023)

135 Fosfomycin Susceptibilities Among Uropathogenic Extended Spectrum Beta-Lactamase-producing Enterobacteriacea
por: Abbo, Lilian, et al.
Publicado: (2014)

2396. Fosfomycin Resistance Among Carbapenem-Resistant Enterobacteriaceae Clinical Isolates in Connecticut, 2017
por: Snayd, Mary, et al.
Publicado: (2018)

Susceptibility of Escherichia coli from Community-Acquired Urinary Tract Infection to Fosfomycin, Nitrofurantoin, and Temocillin in Korea
por: Seo, Mi-Ran, et al.
Publicado: (2014)

In vitro effect of fosfomycin on multi-drug resistant gram-negative bacteria causing urinary tract infections
por: Gopichand, Pallam, et al.
Publicado: (2019)

1417. Fosfomycin Use in the Treatment of Complicated Urinary Tract Infections at a Veterans Affairs Medical Center
por: Lee, Ryan, et al.
Publicado: (2021)

Activity of temocillin and 15 other agents, including fosfomycin and colistin, against Enterobacteriaceae in Hong Kong
por: Ip, Margaret, et al.
Publicado: (2017)

Fosfomycin Dosing Regimens based on Monte Carlo Simulation for Treated Carbapenem-Resistant Enterobacteriaceae Infection
por: Kanchanasurakit, Sukrit, et al.
Publicado: (2020)

In Vitro and In Vivo Studies of Oritavancin and Fosfomycin Synergism against Vancomycin-Resistant Enterococcus faecium
por: Lagatolla, Cristina, et al.
Publicado: (2022)

Susceptibility and Virulence of Enterobacteriaceae Isolated from Urinary Tract Infections in Benin
por: Assouma, Funkè F., et al.
Publicado: (2023)

Bacterial sensitivity to fosfomycin in pregnant women with urinary infection
por: Souza, Rodrigo Batista, et al.
Publicado: (2015)

Role of Glycolipids in the Pathogenesis of Enterococcus faecalis Urinary Tract Infection
por: Diederich, Ann-Kristin, et al.
Publicado: (2014)

Effective Treatment for Uncomplicated Urinary Tract Infections with Oral Fosfomycin, Single Center Four Year Retrospective Study
por: Fajfr, Miroslav, et al.
Publicado: (2020)

Fosfomycin vs Ertapenem for Outpatient Treatment of Complicated Urinary Tract Infections: A Multicenter, Retrospective Cohort Study
por: Wald-Dickler, Noah, et al.
Publicado: (2021)

Pharmacokinetic/Pharmacodynamic Analysis of Oral Calcium Fosfomycin: Are Urine Levels Sufficient to Ensure Efficacy for Urinary Tract Infections?
por: Rodríguez-Gascón, Alicia, et al.
Publicado: (2023)

Frequency of colistin and fosfomycin resistance in carbapenem-resistant Enterobacteriaceae from a tertiary care hospital in Karachi
por: Qamar, Salima, et al.
Publicado: (2017)

Dose Optimization of Combined Linezolid and Fosfomycin against Enterococcus by Using an In Vitro Pharmacokinetic/Pharmacodynamic Model
por: Mao, Jun, et al.
Publicado: (2021)

High Prevalence and Overexpression of Fosfomycin-Resistant Gene fosX in Enterococcus faecium From China
por: Xin, Ling, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dcdard49rbpromi7gocqbktlrn